Summarized & reviewed by The Peptide Dispatch Editorial Team · Last reviewed October 25, 2026
TL;DR Eloralintide (LY3841136) is Eli Lilly's once-weekly amylin receptor agonist, not a GLP-1. It lasts a week because a C20 fatty acid tail lets it ride on albumin in your blood, the same half-life trick used by semaglutide and tirzepatide. In its 48-week Phase 2 trial (263 adults, The Lancet), weight fell 9.5% to 20.1% versus 0.4% on placebo (PubMed). "Generally well tolerated" is doing heavy…
This dispatch covers Eloralintide Isn't the Ozempic Killer. It's Lilly's Plan to Put You on Two Shots Forever. in the Hot Takes research category, authored by The Peptide Dispatch Editorial Team. Estimated reading time: 8 minutes. The Peptide Dispatch curates peer-reviewed peptide research for self-directed learners. All summaries are presented for Research Use Only and do not constitute medical advice.
TL;DR
Last reviewed: October 25, 2026
You've probably seen it spelled "elorilintide." It's eloralintide. And if someone told you it's "the albumin drug," that's half right. Albumin isn't how it works. Albumin is how it stays.
Native amylin is a hormone your pancreas releases alongside insulin. It slows stomach emptying and tells your brain you're full. The problem is that it clumps into fibrils and clears in minutes. Eloralintide fixes both: an engineered amino-acid backbone that prefers the amylin receptor over the calcitonin receptor, plus a C20 fatty diacid tail that binds albumin, which has a roughly 19-day half-life of its own (Sci Rep, 2021). Albumin becomes a slow-release depot. That's why it's a weekly shot.
That's clever chemistry. It is not a new idea. It's the same delivery system that made semaglutide a weekly drug.
| Arm (48 weeks) | Weight change | Nausea | Fatigue |
|---|---|---|---|
| Placebo | −0.4% | 14% | 12% |
| 1 mg | −9% | 11% | 0% |
| 3 mg | −12% | 13% | 13% |
| 6 mg | −18% | 64% | 29% |
| 9 mg | −20% | 33% | 43% |
| 6→9 mg escalation | −20% | 54% | 46% |
| 3→6→9 mg escalation | −16% | 25% | 21% |
Source: Billings et al., Lancet 2025;406:2631–2643 (abstract; full arm-level figures reported by CareNet). Weight figures are the efficacy estimand, which counts people while they stay on drug.
Twenty percent at 48 weeks with no GLP-1 in the molecule is legitimately impressive. Analysts at BMO called it potentially best in class and pointed to no obvious weight-loss plateau in several arms (BioSpace).
Now read the side-effect columns.
Lilly's November 2025 release and the Lancet authors both describe eloralintide as generally well tolerated. The events were mostly rated mild to moderate. Fair.
But "mild" fatigue in nearly half of a dose group for most of a year is not nothing to an executive running a company, a parent, or anyone who trains. The early pitch for amylin drugs was gentler than GLP-1s. Phase 1 looked that way, with decreased appetite as the most common event and nausea around 8% (DelveInsight summary of ADA 2025 data). At the doses that produce the headline numbers, Phase 2 did not.
The honest read: the slow 3→6→9 mg escalation cut nausea to 25% and fatigue to 21%, and it still delivered 16%. The table suggests slower titration matters more than the top dose. Lilly hasn't publicly disclosed the exact Phase 3 escalation schedule, so watch for it.
New research, FDA peptide updates, and what users are reporting. One email a week. Unsubscribe anytime.
Fatigue is the side effect nobody is talking about. Put it on your radar.
Lilly's September 30, 2026 Phase 2b results for EloraTZP tell you where this is going (Lilly investor release):
Lilly is also running a Phase 3 called ENLIGHTEN-6 that enrolls people who are already on a weekly incretin and still have obesity, then adds eloralintide on top (NCT07392190).
Read that design for what it is. The business model isn't "switch to the gentler drug." It's "you plateaued on drug one, so here's drug two, indefinitely." Nobody has published a single day of off-drug follow-up for eloralintide, and amylin agonists only work while they're in your system. Based on everything known about the GLP-1 class, regain after stopping should be the expectation, not a surprise.
Phase 3 ENLIGHTEN-1 (1,980 participants) started February 2026 with primary completion estimated March 2028 (NCT07321886). Lilly is still running basic kidney and liver dosing studies (NCT07426380, NCT07401862). There is no approved product anywhere.
Lab reagent suppliers already list eloralintide "for research use only" (MedChemExpress). If the pattern from earlier pipeline obesity drugs holds, consumer "research peptide" listings will follow. Two facts to weigh before anyone buys one:
We won't publish dose ranges for a drug with no approved label. A molecule this new also has no established independent testing reference, which means a buyer has no practical way to confirm the vial even contains eloralintide.
Every amylin and GLP-1 trial runs on top of diet and activity counseling, and the drug effect is measured above that baseline. The upstream drivers (sleep debt, visceral fat, insulin resistance, protein intake, and resistance training to protect lean mass during rapid loss) don't stop mattering because a better molecule shows up. A 20% loss that's a large share muscle, followed by regain when the drug stops, is a bad trade.
Eloralintide is real science and probably a real product around 2028. It is not a gentler, cleaner GLP-1 alternative at its effective doses, it's being positioned as a lifelong add-on, and the only version you can buy today is an unverified vial with a misread protocol attached.
Our call: ignore the gray market, watch the Phase 3 escalation data, and fix the foundation now.
What is eloralintide? An investigational once-weekly injectable from Eli Lilly (code LY3841136) that activates amylin receptors to reduce appetite and slow stomach emptying. It is not a GLP-1 drug.
Is eloralintide an albumin drug? No. It's an amylin agonist with a fatty acid tail that binds albumin in the blood, which extends its half-life to support weekly dosing.
How much weight did people lose on eloralintide? 9.5% to 20.1% over 48 weeks in Phase 2, versus 0.4% on placebo, measured while participants stayed on treatment.
What are the side effects of eloralintide? Nausea and fatigue were most common in Phase 2, ranging up to 64% and 46% depending on dose and titration schedule, versus 14% and 12% on placebo.
When will eloralintide be available? Not before Phase 3 results, with primary completion estimated in 2028, followed by FDA review. No legitimate supply exists today.
What is EloraTZP? Lilly's combination of eloralintide and tirzepatide. In Phase 2b it produced up to 23.3% weight loss in adults with type 2 diabetes, with higher side-effect discontinuation than tirzepatide alone.
Disclosure: The Peptide Dispatch shares common ownership with 1836 Wellness, a Houston medical weight-loss clinic. This article is educational, reports what published studies found, and is not medical advice or a recommendation to use any substance. Eloralintide is an investigational drug and is not approved for any use.
New research, FDA peptide updates, and what users are reporting. One email a week. Unsubscribe anytime.
From Our Affiliated Clinic
1836 Wellness offers physician-supervised medical weight loss in Houston, TX. Discussing a compound on this page is not an offer to prescribe or supply it.
Learn about medical weight loss →Disclosure: The Peptide Dispatch and 1836 Wellness are commonly owned by 1836 Wellness LLC. We may benefit financially if you become a client of 1836 Wellness. Learn more.
Educational content — not medical advice. Effects described are drawn from cited research in study subjects.